Rheumatology

 

Upadacitinib Receives Positive CHMP Opinion for Treatment of Non-Radiographic Axial Spondyloarthritis

June 28, 2022

The Committee for Medicinal Products for Human Use (CHMP) recommends approving upadacitinib 15 mg, once daily, for the treatment of active non-radiographic axial spondyloarthritis in adults patients with inflammation and inadequate response to NSAIDs.